<DOC>
	<DOCNO>NCT00157092</DOCNO>
	<brief_summary>The study Phase 1B/2A , uncontrolled , open-label , single-center study individual congenital AAT ( alpha 1-antitrypsin ) deficiency . A baseline bronchoscopy bronchoalveolar lavage ( BAL ) perform 3 maximum 4 week prior first administration study drug . Fifteen eligible subject randomize receive 1 3 dosing regimen rAAT ( 100 mg daily , 100 mg twice daily , 200 mg daily ) administer via nebulization 7 consecutive day . A post-treatment nadir BAL obtain study Day 8 ( 12 hour last dose subject receive drug therapy twice daily 24 hour last dose subject receive study product daily ) . BALs conduct lung lobe/segment . Follow-up visit take place Day 15 Day 36 .</brief_summary>
	<brief_title>Study Effect Aerosolized , Recombinant Alpha 1-Antitrypsin Epithelial Lining Fluid Analytes Subjects With Alpha 1-Antitrypsin Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Signed Informed Consent Male female 18 year age old Documented , endogenous plasma AAT level &lt; 11 µM ( &lt; 80 mg/dL ) , either obtain medical history , document , plasma AAT measure 28 day washout prior replacement therapy Forced expiratory volume 1 second ( FEV1 ) &gt; = 50 % predict , measure 30 minute shortacting inhaled bronchodilator Arterial oxygen percent saturation ( SaO2 , measure use room air ) within normal limit individual study site For subject receive inhaled corticosteroid , inhaled oral β2 agonist ( e.g. , albuterol via meter dose inhaler [ MDI ] ) inhale anticholinergic bronchodilator ( e.g. , ipratropium bromide ) , oral PDE ( phosphodiesterase ) inhibitor , treatment stable dose least 14 day prior enrollment For female childbearing potential , negative urine test pregnancy within 3 day prior enrollment agreement employ adequate birth control measure duration study No clinically significant abnormality detect 12lead electrocardiogram ( ECG ) perform screen visit Laboratory result obtain screen visit , meet follow criterion : Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; = 2 time upper limit normal range ( ULN ) Serum total bilirubin &lt; = 2 time ULN &lt; 2+ proteinuria urine dipstick Serum creatinine &lt; = 1.5 time ULN Absolute neutrophil count &gt; = 1500 cells/mm3 Hemoglobin &gt; = 10.0 g/dL Platelet count &gt; = 100,000/mm3 Clinically significant pulmonary impairment , emphysema and/or chronic bronchitis Moderate severe bronchiectasis Clinically significant cardiac , hemostatic , neurologic impairment , significant medical condition , opinion investigator , would affect subject safety compliance Psychiatric cognitive disturbance illness , recreational drug/alcohol use , opinion investigator , would affect subject safety compliance Acute exacerbation emphysema within 28 day prior screen visit Pregnancy lactation Known history allergy yeast product Medical history precluding use epinephrine rescue medication treatment anaphylaxis Prior history adverse reaction local anesthetic , sedative , BAL procedure , premedication employ study center Use oral parenteral glucocorticosteroids , alpha 1antitrypsin replacement therapy within 28 day prior baseline BAL , use plan study . However , subject may enroll provide ) consent give undergo 28day washout replacement steroid therapy , b ) study procedure do washout complete . Use another investigational drug investigational device within 28 day prior baseline BAL Any upper low respiratory infection within 28 day prior baseline BAL Having receive lung liver transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>